Star Equity Holdings, Inc. (STRR)
USD 2.36
(-2.88%)
USD 2.36
(-2.88%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 11.92 Million USD | -59.64% |
| 2022 | 25.87 Million USD | 69.81% |
| 2021 | 15.24 Million USD | 8.96% |
| 2020 | 13.98 Million USD | -36.75% |
| 2019 | 22.11 Million USD | 21.04% |
| 2018 | 18.27 Million USD | -35.67% |
| 2017 | 28.4 Million USD | -20.6% |
| 2016 | 35.77 Million USD | 99.75% |
| 2015 | 17.9 Million USD | 7.63% |
| 2014 | 16.64 Million USD | 17.88% |
| 2013 | 14.11 Million USD | 7.82% |
| 2012 | 13.09 Million USD | -11.29% |
| 2011 | 14.75 Million USD | 22.94% |
| 2010 | 12 Million USD | -40.65% |
| 2009 | 20.22 Million USD | 0.77% |
| 2008 | 20.07 Million USD | -2.18% |
| 2007 | 20.51 Million USD | 7.66% |
| 2006 | 19.05 Million USD | 25.01% |
| 2005 | 15.24 Million USD | -29.93% |
| 2004 | 21.75 Million USD | 31.33% |
| 2003 | 16.56 Million USD | 48.24% |
| 2002 | 11.17 Million USD | 72.75% |
| 2001 | 6.46 Million USD | 276.62% |
| 2000 | -3.66 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.12 Million USD | -59.29% |
| 2024 Q2 | 1.56 Million USD | 96.45% |
| 2023 Q4 | 2.77 Million USD | 25.78% |
| 2023 Q3 | 2.2 Million USD | -15.37% |
| 2023 FY | 10.44 Million USD | -59.64% |
| 2023 Q1 | 7.59 Million USD | -18.51% |
| 2023 Q2 | 2.6 Million USD | -65.72% |
| 2022 FY | 25.87 Million USD | 69.81% |
| 2022 Q1 | 4.66 Million USD | -32.54% |
| 2022 Q2 | 2.42 Million USD | -48.08% |
| 2022 Q3 | 5.79 Million USD | 139.53% |
| 2022 Q4 | 9.31 Million USD | 60.68% |
| 2021 Q3 | 3.74 Million USD | 149.14% |
| 2021 Q2 | 1.5 Million USD | -51.12% |
| 2021 FY | 15.24 Million USD | 8.96% |
| 2021 Q1 | 3.07 Million USD | -20.92% |
| 2021 Q4 | 6.91 Million USD | 84.47% |
| 2020 FY | 13.98 Million USD | -36.75% |
| 2020 Q2 | 4.02 Million USD | -9.34% |
| 2020 Q3 | 4.83 Million USD | 20.09% |
| 2020 Q4 | 3.89 Million USD | -19.52% |
| 2020 Q1 | 4.44 Million USD | -44.03% |
| 2019 FY | 22.11 Million USD | 21.04% |
| 2019 Q4 | 7.93 Million USD | 52.69% |
| 2019 Q1 | 3.98 Million USD | 6.47% |
| 2019 Q2 | 5 Million USD | 25.7% |
| 2019 Q3 | 5.19 Million USD | 3.84% |
| 2018 Q4 | 3.73 Million USD | -14.2% |
| 2018 Q3 | 4.35 Million USD | -21.72% |
| 2018 FY | 18.27 Million USD | -35.67% |
| 2018 Q1 | 4.6 Million USD | -39.56% |
| 2018 Q2 | 5.56 Million USD | 20.84% |
| 2017 Q1 | 7.1 Million USD | -17.76% |
| 2017 FY | 28.4 Million USD | -20.6% |
| 2017 Q4 | 7.62 Million USD | 14.79% |
| 2017 Q3 | 6.64 Million USD | -5.59% |
| 2017 Q2 | 7.03 Million USD | -1.04% |
| 2016 Q1 | 9.06 Million USD | 93.2% |
| 2016 Q4 | 8.64 Million USD | 4.11% |
| 2016 Q3 | 8.3 Million USD | -14.99% |
| 2016 FY | 35.77 Million USD | 99.75% |
| 2016 Q2 | 9.76 Million USD | 7.72% |
| 2015 Q2 | 4.76 Million USD | 30.67% |
| 2015 FY | 17.9 Million USD | 7.63% |
| 2015 Q4 | 4.69 Million USD | -2.29% |
| 2015 Q1 | 3.64 Million USD | -14.85% |
| 2015 Q3 | 4.8 Million USD | 0.73% |
| 2014 Q1 | 3.44 Million USD | -6.67% |
| 2014 Q2 | 4.5 Million USD | 30.88% |
| 2014 FY | 16.64 Million USD | 17.88% |
| 2014 Q4 | 4.28 Million USD | -2.84% |
| 2014 Q3 | 4.4 Million USD | -2.13% |
| 2013 Q2 | 3.79 Million USD | 34.65% |
| 2013 FY | 14.11 Million USD | 7.82% |
| 2013 Q4 | 3.68 Million USD | -3.4% |
| 2013 Q3 | 3.81 Million USD | 0.66% |
| 2013 Q1 | 2.81 Million USD | 7.93% |
| 2012 FY | 13.09 Million USD | -11.29% |
| 2012 Q3 | 3.12 Million USD | -15.0% |
| 2012 Q2 | 3.68 Million USD | 0.25% |
| 2012 Q1 | 3.67 Million USD | 18.68% |
| 2012 Q4 | 2.61 Million USD | -16.59% |
| 2011 Q1 | 3.51 Million USD | -2.47% |
| 2011 FY | 14.75 Million USD | 22.94% |
| 2011 Q4 | 3.09 Million USD | -25.45% |
| 2011 Q3 | 4.15 Million USD | 3.91% |
| 2011 Q2 | 3.99 Million USD | 13.5% |
| 2010 FY | 12 Million USD | -40.65% |
| 2010 Q1 | 3.37 Million USD | -28.48% |
| 2010 Q4 | 3.6 Million USD | 15.86% |
| 2010 Q3 | 3.11 Million USD | 63.21% |
| 2010 Q2 | 1.9 Million USD | -43.42% |
| 2009 FY | 20.22 Million USD | 0.77% |
| 2009 Q2 | 5.88 Million USD | 15.25% |
| 2009 Q3 | 4.51 Million USD | -23.35% |
| 2009 Q1 | 5.1 Million USD | -18.65% |
| 2009 Q4 | 4.71 Million USD | 4.48% |
| 2008 Q1 | 4.41 Million USD | -1.76% |
| 2008 Q2 | 4.55 Million USD | 3.22% |
| 2008 Q3 | 4.82 Million USD | 5.88% |
| 2008 Q4 | 6.28 Million USD | 30.21% |
| 2008 FY | 20.07 Million USD | -2.18% |
| 2007 Q4 | 4.49 Million USD | -5.91% |
| 2007 Q1 | 5.44 Million USD | 10.84% |
| 2007 Q2 | 5.81 Million USD | 6.76% |
| 2007 FY | 20.51 Million USD | 7.66% |
| 2007 Q3 | 4.77 Million USD | -17.83% |
| 2006 Q2 | 5.67 Million USD | 29.11% |
| 2006 Q3 | 4.08 Million USD | -28.0% |
| 2006 FY | 19.05 Million USD | 25.01% |
| 2006 Q1 | 4.39 Million USD | 34.38% |
| 2006 Q4 | 4.91 Million USD | 20.23% |
| 2005 Q3 | 3.4 Million USD | -0.06% |
| 2005 Q4 | 3.26 Million USD | -4.11% |
| 2005 FY | 15.24 Million USD | -29.93% |
| 2005 Q1 | 5.15 Million USD | -6.1% |
| 2005 Q2 | 3.41 Million USD | -33.86% |
| 2004 Q4 | 5.49 Million USD | -4.52% |
| 2004 Q2 | 5.66 Million USD | 16.86% |
| 2004 FY | 21.75 Million USD | 31.33% |
| 2004 Q3 | 5.75 Million USD | 1.52% |
| 2004 Q1 | 4.84 Million USD | 0.0% |
| 2003 Q2 | 3.76 Million USD | 7.69% |
| 2003 Q1 | 3.49 Million USD | 0.0% |
| 2003 FY | 16.56 Million USD | 48.24% |
| 2002 FY | 11.17 Million USD | 72.75% |
| 2001 FY | 6.46 Million USD | 276.62% |
| 2000 FY | -3.66 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bionano Genomics, Inc. | 9.56 Million USD | -24.671% |
| Prenetics Global Limited | 8.82 Million USD | -35.064% |
| CareDx, Inc | 178.32 Million USD | 93.312% |
| Exact Sciences Corporation | 1.84 Billion USD | 99.354% |
| Exagen Inc. | 29.45 Million USD | 59.512% |
| Inotiv, Inc. | 165.44 Million USD | 92.791% |
| Guardant Health, Inc. | 336.89 Million USD | 96.46% |
| Biodesix, Inc. | 36.07 Million USD | 66.943% |
| BioNexus Gene Lab Corp. | 1.32 Million USD | -797.03% |
| Precipio, Inc. | 6.01 Million USD | -98.172% |
| iSpecimen Inc. | 5.1 Million USD | -133.481% |
| Natera, Inc. | 492.74 Million USD | 97.58% |
| Aspira Women's Health Inc. | 5.26 Million USD | -126.644% |
| Standard BioTools Inc. | 50.45 Million USD | 76.361% |
| 23andMe Holding Co. | 99.37 Million USD | 87.999% |
| Castle Biosciences, Inc. | 174.8 Million USD | 93.178% |
| Personalis, Inc. | 18.2 Million USD | 34.501% |
| Aclaris Therapeutics, Inc. | 13.16 Million USD | 9.432% |
| Applied DNA Sciences, Inc. | 5.53 Million USD | -115.526% |
| OpGen, Inc. | -90.69 Thousand USD | 13249.712% |
| T2 Biosystems, Inc. | -8.17 Million USD | 245.973% |
| Myriad Genetics, Inc. | 476.4 Million USD | 97.497% |
| ICON Public Limited Company | 1.81 Billion USD | 99.343% |
| NeoGenomics, Inc. | 244.6 Million USD | 95.124% |
| Star Equity Holdings, Inc. | 11.92 Million USD | 0.0% |
| IDEXX Laboratories, Inc. | 2.18 Billion USD | 99.455% |
| RadNet, Inc. | 93 Million USD | 87.176% |
| MDxHealth SA | 43.92 Million USD | 72.852% |
| Psychemedics Corporation | 8.41 Million USD | -41.757% |
| Illumina, Inc. | 2.74 Billion USD | 99.565% |
| Check-Cap Ltd. | -212 Thousand USD | 5725.472% |
| Twist Bioscience Corporation | 133.34 Million USD | 91.057% |
| DarioHealth Corp. | 5.98 Million USD | -99.298% |
| Fulgent Genetics, Inc. | 104.45 Million USD | 88.583% |
| Sera Prognostics, Inc. | 96 Thousand USD | -12322.917% |
| ENDRA Life Sciences Inc. | -275.45 Thousand USD | 4429.627% |
| OPKO Health, Inc. | 318.12 Million USD | 96.251% |
| Medpace Holdings, Inc. | 524.5 Million USD | 97.726% |
| Neogen Corporation | 463.9 Million USD | 97.429% |
| Intelligent Bio Solutions Inc. | 1.42 Million USD | -736.545% |
| Prenetics Global Limited | 8.82 Million USD | -35.064% |
| Mainz Biomed B.V. | 509.65 Thousand USD | -2239.996% |
| bioAffinity Technologies, Inc. | 791.61 Thousand USD | -1406.54% |
| Trinity Biotech plc | 19.45 Million USD | 38.684% |
| Neuronetics, Inc. | 51.7 Million USD | 76.935% |
| Sotera Health Company | 577.15 Million USD | 97.934% |
| bioAffinity Technologies, Inc. | 791.61 Thousand USD | -1406.54% |